Download PDF
Am J Perinatol 2003; 20(6): 283-288
DOI: 10.1055/s-2003-42774
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Indicative Markers of Cell Proliferation and Apoptosis During the Perinatal Period

Angeliki Sarandakou, Ariadne Malamitsi-Puchner, Efthimia Protonotariou, Urania Rigopoulou, Basiliki Papagianni, George Creatsas
  • 2nd Department of Obstetrics and Gynaecology, University of Athens, Aretaieion Hospital, Athens, Greece
Further Information

Publication History

Publication Date:
06 October 2003 (online)

    Permissions and Reprints

ABSTRACT

Tissue polypeptide-specific antigen (TPS), an indicative marker of cell proliferation and soluble Fas (sFas), an antiapoptotic molecule were determined in neonatal serum (day 1-N1 and day 4-N4 of life), compared with maternal serum (MS) and umbilical cord serum (UC) to study changes of these markers during the perinatal period. Serum TPS and sFas concentrations were measured in 33 healthy, termed neonates, their mothers and 25 healthy nonpregnant controls (CS), age-matched to the mothers. TPS serum concentrations were significantly elevated in N1 and N4 as compared to CS (p < 0.0001 and p < 0.0003), increasing significantly from UC to N1 (p < 0.0001) and decreasing thereafter in N4 (p < 0.0002). MS serum concentrations, being significantly higher than CS (p < 0.0001), UC (p < 0.0001) and N4 (p < 0.003), but lower than N1 (p < 0.02) were strongly depended on the mode of delivery (p < 0.001). Serum concentrations of sFas, being lower in UC than in MS or CS (p < 0.0001), increased significantly in N4 samples (p < 0.01). A strong correlation was found between sFas serum concentrations in N1 and N4 (r = 0.65; p < 0.001). Our results demonstrate significant perinatal changes in TPS and sFas serum concentrations, possibly indicating gradual decrease of proliferation and apoptosis in early postnatal life.

KEYWORDS

Mode of delivery - sFas TPS - umbilical cord

REFERENCES

  • 1 Malamitsi-Puchner A, Tziotis J, Protonotariou E, Sarandakou A, Creatsas G. Angiogenic factors in the perinatal period: diversity in biological functions reflected in their serum concentration soon after birth.  Ann N Y Acad Sci . 2000;  900 169-173
    PubMedGoogle Scholar
  • 2 Sarandakou A, Protonotariou E, Rizos D. et al . Serum leptin concentrations during the perinatal period.  Am J Perinatol . 2000;  17 325-328
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Malamitsi-Puchner A, Tziotis I, Protonotariou E, Xyni K, Sarandakou A, Creatsas G. Heparin-binding angiogenin factors (basic fibroblast growth factor and vascular endothelial growth factor) in early neonatal life.  Pediatr Res . 1999;  45 877-880
    PubMedGoogle Scholar
  • 4 Shapiro R, Vallee B L. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.  Proc Natl Acad Sci U S A . 1987;  84 2238-2241
    PubMedGoogle Scholar
  • 5 Shalaby F, Rossant J, Yamaguchi T P. et al . Failure of blood island formation and vasculogenesis in FLK-1 deficient mice.  Nature . 1995;  376 62-66
    CrossrefPubMedGoogle Scholar
  • 6 Sarandakou A, Giannaki G, Malamitsi-Puchner A. et al . Inflammatory cytokines in newborn infants.  Mediators Inflamm . 1998;  7 309-312
    CrossrefPubMedGoogle Scholar
  • 7 Phocas I, Sarandakou A, Giannaki G, Malamitsi-Puchner A, Rizos D, Zourlas P A. Soluble intercellular adhesion molecule-1 in newborn infants.  Eur J Pediatr . 1998;  157 153-156
    CrossrefPubMedGoogle Scholar
  • 8 Malamitsi-Puchner A, Sarandakou A, Tziotis J, Trikka P, Creatsas G. Evidence for a suppression of apoptosis in early postnatal life.  Acta Obstet Gynecol Scand . 2001;  80 994-997
    CrossrefPubMedGoogle Scholar
  • 9 Skalli O, Goldman R D. Recent insights into the assembly, dynamics and function of intermediate filament networks.  Cell Motil Cytoskeleton . 1991;  19 67-79
    CrossrefPubMedGoogle Scholar
  • 10 Madersbacher S, Schollhammer A, Kramer G, Marberger M. TPS in prostate cancer.  Aktuel Urol . 1993;  24 36-39
    PubMedGoogle Scholar
  • 11 Inaba N, Fukasawa I, Okajima Y. et al . Immunoradiometrical measurment of tissues polypeptide specific antigen (TPS) in normal, healthy nonpregnant and pregnant Japanese women.  Acta Oceania J Obstet Gynaecol . 1993;  19 459-466
    PubMedGoogle Scholar
  • 12 Bjorklund B. Tumor markers TPA, TPA-S, and cytokeratins: a working hypothesis.  Tumordiagn Ther . 1992;  13 78-80
    PubMedGoogle Scholar
  • 13 Sarandakou A, Phocas I, Botsis D. et al . Tumour-associated antigens CEA, CA125, SCC and TPS in gynecological cancer.  Eur J Gynaecol Oncol . 1998;  19 73-77
    PubMedGoogle Scholar
  • 14 Negata S, Goldstein P. The Fas death factor.  Science . 1995;  267 1449-1456
    PubMedGoogle Scholar
  • 15 Alderson M R, Tough T W, Davis-Smith T. et al . Fas ligand mediates activation induced cell death in human T lymphocytes.  J Exp Med . 1995;  181 71-77
    CrossrefPubMedGoogle Scholar
  • 16 Arase H, Arase N, Saito T. Fas mediated cytotoxicity by freshly isolated natural killer cells.  J Exp Med . 1995;  181 1235-1238
    CrossrefPubMedGoogle Scholar
  • 17 Liles W C, Kiener P A, Ledbetter J A, Aruffo A, Klebanoff S J. Differential expression of Fas (CD 95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.  J Exp Med . 1996;  184 429-440
    CrossrefPubMedGoogle Scholar
  • 18 Bergant A, Kirchler H, Schrocksnadel H, Daxenbichler G. Tissue polypeptide antigen during parturition and puerperium.  Gynecol Obstet Invest . 1996;  41 237-239
    PubMedGoogle Scholar
  • 19 Rebhandl W, Felberbauer F X, Paya K. et al . Tissue polypeptide-specific antigen (TPS) in pediatric malignancies.  Anticancer Res . 1997;  17 2865-2868
    PubMedGoogle Scholar
  • 20 Rebhandl W, Felberbauer F X, Paya K. et al . Tissue polypeptide-specific antigen in pediatirc patients: assessment of normal values.  Med Pediatr Oncolol . 1997;  29 218-221
    PubMedGoogle Scholar
  • 21 Inaba N, Fukazawa I, Ota Y. et al . Tissue polypeptide antigen and cancer antigen 125 in pregnancy: these two cancer-related antigens are oncofetal?.  Acta Obstet Gynecol Jpn . 1985;  37 2139-2140
    PubMedGoogle Scholar
  • 22 Bellanti J A, Boner A L, Valleta E. Immunology of the fetus and newborn In: Klein J, Remington J, eds. Infectious Diseases of The Fetus and Newborn Infant.  New York: Saunders 1989: 850-871
    Google Scholar
  • 23 Iwama H, Akutsu H, Kuretake S, Tohma J, Nakamura N. Serum concentrations of soluble Fas antigen and soluble Fas ligand in mother and newborn.  Arch Gynecol Obstet . 2000;  263 108-110
    CrossrefPubMedGoogle Scholar
  • 24 Kim H S, Hwang K K, Seo J W. et al . Apoptosis and regulation of Bax and Bcl-X proteins during neonatal vascular remodeling.  Arterioscler Thromb Vasc Biol . 2000;  20 957-963
    PubMedGoogle Scholar
  • 25 Joshi S S, Tarantolo S R, Kuszynski C A, Kessinger A. Antitumor therapeutic potential of activated human umbilical blood cells leukemia and breast cancer.  Clin Cancer Res . 2000;  6 4351-4358
    PubMedGoogle Scholar
  • 26 Smith S C, Baker P N, Symonds E M. Increased placental apoptosis in intrauterine growth restriction.  Am J Obstet Gynecol . 1997;  177 1395-1401
    PubMedGoogle Scholar
  • 27 Kelliher M A, Grimm S, Ishida Y, Kuo F, Stranger B Z, Leder P.The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity .  1998;  8 297-303
    PubMedGoogle Scholar
  • 28 Tsao C Y, Mendell J R, Luquette M, Dixon B, Morrow G. Mitochondrial DNA depletion in children.  J Child Neurol . 2000;  15 822-824
    PubMedGoogle Scholar
  • 29 Olson J M, Asakura A, Snider L. et al . NeuroD2 is necessary for development and survival of central nervous cystem neurons.  Dev Biol . 2001;  234 174-187
    CrossrefPubMedGoogle Scholar
  • 30 Gilbert S, Loranger A, Daigle N, Marceau N. Simple epithilium keratins 8 and 18 provide resistence to Fas mediated apoptosis: the protection occurs through a receptor-targeting modulation.  J Cell Biol . 2001;  154 763-773
    CrossrefPubMedGoogle Scholar
      >